A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
Carregando...
Arquivos
Data
2015
Autores
Pertega-Gomes, Nelma
Felisbino, Sergio [UNESP]
Massie, Charlie E.
Vizcaino, Jose R.
Coelho, Ricardo
Sandi, Chiranjeevi
Simões-Sousa, Susana
Jurmeister, Sarah
Ramos-Montoya, Antonio
Asim, Mohammad
Título da Revista
ISSN da Revista
Título de Volume
Editor
Wiley-Blackwell
Resumo
Metabolic adaptation is considered an emerging hallmark of cancer, whereby cancer cells exhibit high rates of glucose consumption with consequent lactate production. To ensure rapid efflux of lactate, most cancer cells express high levels of monocarboxylate transporters (MCTs), which therefore may constitute suitable therapeutic targets. The impact of MCT inhibition, along with the clinical impact of altered cellular metabolism during prostate cancer (PCa) initiation and progression, has not been described. Using a large cohort of human prostate tissues of different grades, in silico data, in vitro and ex vivo studies, we demonstrate the metabolic heterogeneity of PCa and its clinical relevance. We show an increased glycolytic phenotype in advanced stages of PCa and its correlation with poor prognosis. Finally, we present evidence supporting MCTs as suitable targets in PCa, affecting not only cancer cell proliferation and survival but also the expression of a number of hypoxia-inducible factor target genes associated with poor prognosis. Herein, we suggest that patients with highly glycolytic tumours have poorer outcome, supporting the notion of targeting glycolytic tumour cells in prostate cancer through the use of MCT inhibitors.
Descrição
Palavras-chave
Cell metabolism, Metabolic targets, Monocarboxylate transporters, Poor prognosis markers, Prostate cancer
Como citar
The Journal Of Pathology, v. 236, n. 4, p. 517-530, 2015.